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Available online 23 February 2016Understanding the circulating Mycobacterium tuberculosis resistance mutations is vital for better TB control
strategies, especially to inform a new MDR-TB treatment programme. We complemented the phenotypic drug
susceptibility testing (DST) based drug resistance surveys (DRSs) conducted in Uganda between 2008 and
2011withWhole Genome Sequencing (WGS) of 90Mycobacterium tuberculosis isolates phenotypically resistant
to rifampicin and/or isoniazid to better understand the extent of drug resistance.
A total of 31 (34.4 %) patients hadMDR-TB, 5 (5.6 %)mono-rifampicin resistance and 54 (60.0 %)mono-isoniazid
resistance by phenotypic DST. Pyrazinamide resistance mutations were identiﬁed in 32.3% of the MDR-TB
patients. Resistance to injectable agents was detected in 4/90 (4.4%), and none to ﬂuoroquinolones or novel
drugs. Compensatory mutations in rpoC were identiﬁed in two patients. The sensitivity and speciﬁcity of drug
resistance mutations compared to phenotypic DST were for rpoB 88.6% and 98.1%, katG 60.0% and 100%, fabG1
16.5% and 100%, katG and/or fabG1 71.8% and 100%, embCAB 63.0% and 82.5%, rrs 11.4% and 100%, rpsL 20.5%
and 95.7% and rrs and/or rpsL 31.8% and 95.7%.
Phylogenetic analysis showed dispersedMDR-TB isolate, with only one cluster of three Beijing family from South
West Uganda.
Among tuberculosis patients in Uganda, resistance beyond ﬁrst-line drugs as well as compensatory mutations
remain low, and MDR-TB isolates did not arise from a dominant clone. Our ﬁndings show the potential use of
sequencing for complementing DRSs or surveillance in this setting,with good speciﬁcity compared to phenotypic
DST. The reported high conﬁdencemutations can be included inmolecular assays, and population-based studies
can track transmission of MDR-TB including the Beijing family strains in the South West of the country.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Whole genome sequencing
Complement
Tuberculosis
Drug resistance surveys1. Introduction
Tuberculosis remains one of the major global health problems with
more than 1.8 million deaths worldwide (WHO, 2014). The increasing
prevalence of multi-drug resistant tuberculosis (MDR-TB), resistant to
rifampicin (RIF) and isoniazid (INH), has continued to threaten public
health efforts towards tuberculosis control. The emergence of exten-
sively drug-resistant (XDR) tuberculosis, i.e. MDR-TB with additional
resistance to any ﬂuoroquinolone and at least one of the second-line
injectable agents (kanamycin, amikacin or capreomycin), has furtherInstitute of Tropical Medicine,
ooba).
. This is an open access article undercomplicated control efforts (WHO, 2010). The prevalence of MDR-TB
in Uganda in the year 2011 was reported as low among new cases
(1.4%), and, as expected, higher among previously treated patients,
12.1% (Lukoye et al., 2013).
Previous studies have reported imperfect agreement between
genotypic and phenotypic drug susceptibility testing (DST) methods
(Ocheretina et al., 2014; Rigouts et al., 2013). The recent WHO, 2015
guidelines for surveillance of drug resistant tuberculosis recommends
incorporation of molecular technologies into surveys, either alone or
as a screening tool prior to culture-based methods (WHO, 2015).
However, drug resistance conferring mutations that are normally
missed in phenotypic DST (Jamieson et al., 2014; Ocheretina et al.,
2014; Walker et al., 2015) or by the rapid molecular methods such as
XpertMTB/RIF assay, for resistance to RIF(Sanchez-Padilla et al., 2015),the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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a susceptible phenotypic DST, have been found to have poor clinical out-
comes (Ho et al., 2013; Van Deun et al., 2015). Genotypic assays on the
other hand, are known to produce rapid results but they may also miss
certain clinically importantmutations thatmay be outside the target re-
gion or due to other mechanisms of resistance (Merker et al., 2013; Sun
et al., 2012). RIF resistance conferringmutation rpoB S531L is associated
with the acquisition of rpoA and rpoC compensatory mutations, a com-
bination that is found to be strongly associatedwith improved transmis-
sibility of strains in patient populations (Casali et al., 2014; de Vos et al.,
2013; Lanzas et al., 2013). From a model-based analysis, ﬁtness costs of
resistance-conferring mutations have been reported as key determi-
nants for the future burden of drug resistant tuberculosis (Knight
et al., 2015). Moreover, use of WGS data has been found to be vital in
prediction ofMycobacterium tuberculosis drug susceptibility and resis-
tance (Walker et al., 2015).
To-date, the contribution and agreement of phenotypic and geno-
typic testing for such resistance-conferring mutations to ﬁrst and
second-line tuberculosis drugs in Uganda, where MDR-TB treatment
has been available since 2012, is unknown. Documenting the prevalent
resistance-conferring mutations, especially before an MDR-TB
treatment programme, can provide evolutionary lessons that are vital
in the implementation of molecular diagnostic tools (Niemann and
Supply, 2014), anti-TB drug resistance surveillance, and interruption
of the transmission chain of these strains (Nardell and Dharmadhikari,
2010; Trauner et al., 2014; Wells et al., 2013).
In the current study, we aimed at complementing the conventional
DST used in the anti-tuberculosis DSRs conducted in Uganda with
WGS. This study contributes baseline estimates of the proportions of
resistance-conferring mutations to ﬁrst and second-line tuberculosis
drugs in Uganda, which can be applied in the design and deployment
of future drug regimens, as well as monitoring resistance to new drug
classes.
2. Materials and methods
2.1. Study setting and population
The demographic and clinical information, as well asMycobacterium
tuberculosis isolates, were obtained from two tuberculosis DRSs done in
Uganda: one done in the capital city of Kampala (August to December
2008), and a nationwide survey (December 2009–February 2011)
(Lukoye et al., 2013, 2011), with no overlap between surveys. For
the present study, we considered participants having isolates with phe-
notypic resistance to RIF and/or INH, the two most powerful ﬁrst-line
anti-tuberculosis drugs.
2.2. Culture and drug susceptibility testing
Standard Löwenstein-Jensen (LJ) proportional method was used for
primary isolation and to test for susceptibility to RIF (40 mg/mL), INH
(0.2 mg/mL) and streptomycin (STR) (10 mg/mL) for which results
were interpreted at week six, and for ethambutol (EMB; 2 mg/mL)
which was interpreted at week four (Lukoye et al., 2013, 2011). All
MDR isolates were phenotypically tested for kanamycin and oﬂoxacin
resistance and no phenotypic resistance to either drug was reported.
For external quality control, random samples resistant to RIF and/or
INH-15 from the Kampala survey and 73 from the national survey-
were retested at the supra-national reference laboratory in Borstel
(Germany). Accuracy was conﬁrmed to exceed 95% for all ﬁrst-line
drugs tested (Lukoye et al., 2013, 2011).
2.3. Spoligotyping
From a portion of the frozen stock of Mycobacterium tuberculosis
isolates received at the Institute of Tropical Medicine (ITM), Antwerp,Belgium, we performed spoligotyping. Primers (DRa and DRb) targeting
thedirect repeat (DR) region of the genomeofMycobacterium tuberculosis
and an in-house membrane were used according to the standard
spoligotyping protocol as described (Kamerbeek et al., 1997).2.4. Genomic DNA extraction
A portion of each frozen stock was sub-cultured on LJ medium for
WGS. Scraped colonies were transferred to 150 μl of a buffer containing
0.5 M Tris (PH 8.5), 0.5 M EDTA and boiled for 5 minutes in a biosafety
level three laboratory. The boiled lysates underwent genomic DNA
(gDNA) extraction as previously described (Kaser et al., 2009), followed
by puriﬁcation in the Maxwell® 16 DNA puriﬁcation Kit AS1020
(Promega, 2014). The extracted gDNA was checked for integrity and
purity using agarose gel electrophoresis and the yield was estimated
by a Qubit 2.0 ﬂuorometer with dsDNA BR assay kits. The puriﬁed
gDNA was used for WGS, at either Genoscreen (Lille, France) or the
Beijing Genomic Institute (BGI; Hong Kong, China), with resulting data
analyzed at ITM.2.5. DNA sequencing and sequence analysis
WGS of theMycobacterium tuberculosis isolates was performed fol-
lowing Illumina TruSeq DNA sample preparation recommendations. The
fastq read pairs were processed in an on-line program, PhyResSE,version
1.0 available at https://bioinf.fz-borstel.de/mchips/phyresse/ (Feuerriegel
et al., 2015). This tool maps fastq reads to theMycobacterium tuberculosis
reference strain H37RV (NC_000962.3) to produce drug resistance
and phylogenetic single nucleotide polymorphisms (SNPs). It allows
fastq ﬁles of up to 2.1 GB and approximately 1,000× coverage. These
SNPs are further used to assign lineage from the literature (Feuerriegel
et al., 2015; Steiner et al., 2014), experiments and other public sources
(Sandgren et al., 2009) and to identify both high conﬁdence (well sup-
ported in the literature) and low conﬁdence (some supporting evidence)
drug-resistance related mutations. The low conﬁdence mutations were
veriﬁed for their references and classiﬁcation in the Tuberculosis Drug
Resistance Mutation Database (TBDreamDB)(Sandgren et al., 2009). The
list of genes and positions analysed for each tuberculosis drug was
based on the well-characterized SNPs collected in the PhyResSE, Resi-
List-Master.v27 (Feuerriegel et al., 2015) available at https://bioinf.fz-
borstel.de/mchips/phyresse/.2.6. Analysis of phenotypic and genotypic discordance for RIF
2.6.1. Determination of RIF MIC
We performed MIC testing for discordant RIF resistant isolates
between survey results and WGS analysis. RIF MICs were performed
using LJ with drug concentrations 10, 20, 40, 80, 160, and 320 μg/mL.
Bacterial suspensions were prepared in sterile 0.01% Tween 80 and
adjusted to McFarland 1. Both drug containing and plain (control) LJ
slants were inoculated with 10−2 and a second control inoculated
with 10−4 of the bacterial suspensions. The inoculated tubes were
incubated at 35 to 38 °C and read after 4 and 6 weeks of incubation.
The lowest concentration with growth less than the 1/100 diluted
control (10−4) tube at week six was interpreted as the MIC-99 value
as per the proportion method (Canetti et al., 1963).2.6.2. rpoB sequencing
From the isolates with RIF discordance between phenotypic DST and
mutation analysis, the rpoB gene was sequenced and analysed as previ-
ously described (Rigouts et al., 2007).
Sequence graphs for the RIF discordant isolateswere investigated for
evidence of hetero-resistance in terms of resistant sub-populations.
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For each set of fastq reads, we undertook quality control using the
nesoni version 0.13 pipeline (https://github.com/Victorian-Bioinfor-
matics-Consortium/nesoni) with a minimum read quality of 10, read
length of 45 and removal of sequence adaptors. Sequenceswere aligned
to the most to the recent common ancestor of the M. tuberculosis
complex (MTBc; H37rv_NC_018143.2) (Comas et al., 2010, 2013). The
nesoni consensus tool was used for SNP calling with reads that mapped
to more than 1 position removed, a minimum coverage of 10 reads,
minimum mapping quality of 20 and minimum base call consensus of
66%. SNPs and indels per isolate were generated using nesoni nway
and a SNP alignment was created using custom python scripts. We
constructed a maximum likelihood tree using Randomized Axelerated
Maximum Likelihood (RAxML) version 8.2, based upon the SNP
alignment and employed a generalized time-reversible (GTR) CAT
model with Stamatakis ascertainment bias correction (Stamatakis,
2014). The phylogenetic tree was visualized in FigTree 1.4.2 (http://
tree.bio.ed.ac.uk/software/ﬁgtree/ accessed 22nd December 2015).
2.7. Data management and analysis
Data were exported to Stata, (Stata Corp LP, College Station TX, USA)
for analysis of frequencies and proportions of lineages and drug resistanceFig. 1. Flow diagram showing the nmutations in relation to phenotypic testing results. Sensitivities and spec-
iﬁcities of the resistance-conferring mutations were calculated with phe-
notypic drug susceptibility results as the reference standard.
Data for the drug resistance-conferring mutations as well as the
phylogenetically informativemutations identiﬁed are provided, supple-
mentary ﬁle 1, computed on 26th October 2015 using PhyResSE v1.0
and H37RV reference strain (NC_000962.3).
2.8. Ethical considerations
For the surveys, ethical approvals were obtained from the Research
and Ethics Committees of Makerere University College of Health
Sciences, Kampala and the Uganda National Council of Science and
Technology. The present sub-study obtained additional approval from
the Institutional Review Board of the ITM (Antwerp, Belgium).
3. Results
3.1. Clinical and phenotypic characteristics of participants
Of the 136 eligible patientswith INH and/or RIF resistance from both
surveys, isolates 25/41 (61.0%) from the Kampala survey and 88/95
(92.6%) from the nationwide survey were available for the currentumber of participants enrolled.
Table 1
Clinical and phenotypic characteristics of participants with Mycobacterium tuberculosis
resistant to rifampicin and/or isoniazid (n = 90).
Parameter Category n (%)
Gender Male 62 (68.9)
Female 28 (31.1)
Age category (years) 18–24 18 (20.0)
25–34 25 (27.8)
35–44 22 (24.4)
N44 25 (27.8)
Median age (IQR) 35 (26–45)
HIV-status Negative 63 (70.0)
Positive 27 (30.0)
Treatment category New 26 (28.9)
Previously treated 64 (71.1)
Drug resistance Mono-RIF 5 (5.6)
Mono-INH 54 (60.0)
MDR 31 (34.4)
MDR (multi-drug resistant)=Resistant to both rifampicin and isoniazid, IQR= interquartile
range, RIF = rifampicin, INH= isoniazid.
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failed subculture. Of the 98 (86.7%) sequenced, four samples had poor
quality sequences and four, processed in one batch, were excluded
from analysis due to laboratory sample switch, recognized through
mismatches of spoligotype patterns between genomes and spoligotype
ﬁlms. The remaining 90/113 (79.6 %), isolates with WGS results were
analysed, Fig. 1.
Of the 90 patients, 62 (68.9 %) were male, median age was 35 years
(IQR; 26–45), 27(30.0%) were HIV-infected and 64 (71.1%) wereFig. 2. Phylogenetic tree showing the distribution of RIF and/or INH resistance by districts in U
(purple). Lineage colour; Beijing (red), CAS-Dehli (green), Harlem (blue), LAM (yellow), S-typpreviously treated for tuberculosis. Isolates with phenotypic mono-RIF
resistance were 5 (5.6%), 54 (60.0%) were mono-INH resistant, and 31
(34.4%) were MDR-TB, Table 1. None of the MDR-TB patients’ isolates
had phenotypic resistance to kanamycin or oﬂoxacin.
From phylogenetic analysis, only two MDR-TB patients from
Mbarara district and one from Rakai district were in a cluster of Beijing
family isolates with identical drug resistance mutations, Fig. 2.3.2. Frequency of Mycobacterium tuberculosis resistance-conferring
mutations
Using sequencing results to predict drug resistance, resistance-
conferring mutations to RIF were identiﬁed in 32/90 (35.6%) isolates.
The most prevalent RIF resistance-conferringmutation was rpoB.S531L,
in 16 (50.0%). Two of the MDR-TB isolates with rpoB.S531L also had a
compensatory mutation in rpoC, N698S and V483A; both were from
patients previously treated for tuberculosis, one of whom was HIV-
infected. Mutations in the rpoB 526 position had the most variation
with ﬁve amino acid exchanges, all classiﬁed as RIF resistant by pheno-
typic DST.
Resistance-conferringmutations to INHwere found in 61/90 (67.8%)
of the isolates. Mutations of the katG.S315T alone were found in 44/61
(72.1%) whereas mutations in the fabG1 promotor region were present
in 9/61 (14.8%) of the isolates and none had inhAmutations. One INH
resistant patient had the ahpC-48 G/A mutation Table 2A).
Resistance-conferring mutations to EMB in the embCAB loci were
found in 28/90 (31.1 %) isolates, with embB.M306V being the mostganda. Taxa colour; MDR-TB (red), INH-mono resistance (blue) and RIF-mono resistance
e (pink), T-unclassiﬁed (orange), T2-Uganda (purple), X1 (black), unknown (grey).
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typically sensitive to EMB.
Resistance to STR due tomutations in the rpsL and rrs loci was found
in 16/90 (17.8%) isolates. Mutations in the rpsL were more frequent at
K43R, 7/16 (43.8%). Resistant-conferring mutation rpsL.K43R was also
found in two isolates which were phenotypically susceptible to STR.
None had mutations in the gidB promoter.
Resistance to PZA at the pncA locuswas identiﬁed in 11/90 (12.2 %) of
the isolates and none with rpsA. A total of nine different resistance-
conferring mutations were identiﬁed (Table 2B). Patients with MDR-TB
(32.3%) also had pncAmutations.
Four (4.4%) MDR-TB patients had resistance-conferring mutations
to injectable agents; one to kanamycin, amikacin and capreomycin
in the rrs gene at positions G1484T and C1402A, one with rrs.A581C
and two with rrs.C517T, the last two conferring resistance to both
STR and amikacin. SNP analysis of the WGS results revealed no
resistance-conferring mutations to ﬂuoroquinolones (FQ), linezolidTable 2A
Frequency ofMycobacterium tuberculosis resistance-conferring mutations.
Drug Locus Mutationab
RIF rpoBc L511P
Q513L
D516V
D516Y + I572F
D516Y
H526D
H526L
H526R
H526T
H526Y
S531L
Total
rpoC N698S
V483A
INH KatG+ ahpC S315T + ahpC-48 G/A
katG+ fabG1 S315T + fabG1.pro-15 C/T
KatG S315T
S315N
S315R
fabG1 pro-8 T/C
pro-15C/T
ahpC 48G/A
Total
EMB embB+ embA G406D + embA.pro-12 C/T
Q497R + embA.pro 12 C/T
Q497R + M306I + embA.pro 12 C/T
embB M306I
M306I
M306V
M306V
M306L
G406A
G406A
G406S
Q497R
Q497R
M306V + G406D
G406A + G406R+M306I
STR rpsL Total
K43R
K43R
K88R
rrs A514C
C517T
905 C-A
906 A-G
Total
Bold values indicate signiﬁcance at most frequent resistance mutation relative to drug.
–Locus number very small to yield meaningful comparisons.
a Italicized mutation = Low conﬁdence mutations.
b All mutations are reported in TBdreamDB (Sandgren et al., 2009).
c BASED on the Escherichia coli rpoB codon numbering system.
d Using LJ; RIF (40 mg/mL), INH (0.2 mg/mL) and STR (10 mg/mL) interpreted at week six a(rrl, rplC), para-aminosalisylic acid (thyA), ethionamide (ethA, inhA,
ndh,mshA), STR, amikacin, capreomycin kanamycin (gidB, tlyA) or kana-
mycin (eis) (Table 2B).
Of the 90 Mycobacterium tuberculosis isolates, SNP analysis of the
WGS for lineages revealed 5 (5.3 %) isolates of the Beijing family (lineage
2), 18 (20.0 %) CAS-Delhi (lineage 3), 2 without any speciﬁc lineage
deﬁning SNPs, but with spoligotype pattern of U and T3-ETH according
to http://tbinsight.cs.rpi.edu/ (Shabbeer et al., 2012), and the remainder
were sub-families within lineage 4 (11 (12.2 %) LAM, 7 (7.8 %) S-type, 36
(40.0%) T2-Uganda, and 11(12.2%) “ill-deﬁned” (X1 = 6, T2 = 1, T = 2
and H1 = 2) (Shabbeer et al., 2012). The majority of the resistant
variants in lineage 4 belonged to the T2-Uganda sub-lineage (Table 3).
3.3. Comparison of genotypic and phenotypic drug resistance testing
Analysis of sequence graph revealed mixed coverage for one discor-
dant isolate with MIC N320, which was excluded from this comparison.Phenotyped Frequency Relative frequency (%)
Sensitive 1 3.1
Resistant 1 3.1
Resistant 2 6.3
Resistant 1 3.1
Resistant 2 6.3
Resistant 4 12.5
Resistant 1 3.1
Resistant 1 3.1
Resistant 1 3.1
Resistant 2 6.3
Resistant 16 50.0
N/A 32 N/A
Resistant 1 –
Resistant 1 –
Resistant 1 1.6
Resistant 1 1.6
Resistant 44 72.1
Resistant 2 3.3
Resistant 2 3.3
Resistant 1 1.6
Resistant 9 14.8
Resistant 1 1.6
N/A 61 N/A
Resistant 1 3.6
Sensitive 1 3.6
Resistant 1 3.6
Resistant 1 3.6
Sensitive 4 14.3
Resistant 6 21.4
Sensitive 1 3.6
Resistant 3 10.7
Resistant 2 7.1
Sensitive 3 10.7
Sensitive 1 3.6
Resistant 1 3.6
Sensitive 1 3.6
Resistant 1 3.6
Sensitive 1 3.6
N/A 28 N/A
Resistant 7 43.8
Sensitive 2 12.5
Resistant 2 12.5
Resistant 1 6.3
Resistant 2 12.5
Resistant 1 6.3
Resistant 1 6.3
N/A 16 N/A
nd EMB (2 mg/mL) interpreted at week four.
Table 2B
Resistance conferring mutations to other drugs.
Drug Locus Mutationa Frequency Relative frequency (%)
Pyrazinamide D12A 1 9.1
P54Q 1 9.1
D63G 1 9.1
F94L 1 9.1
pncA K96R 1 9.1
H137R 1 9.1
R154G 1 9.1
V180F + T142R 1 9.1
V180F 3 27.3
rpsA None 0 N/A
Total 11 N/A
Fluoroquinolone gyrAb/gyrB None – N/A
Kanamycin/ rrs G1484T + C1402A 1 –
amikacin/capreomycin
STR, amikacin, capreomycin kanamycin gidB, tlyA None 0 N/A
STR and amikacin rrs C517T 2 –
A514C 1 –
Linezolid rrl/rplC None 0 N/A
Para-Aminosalisylic_Acid thyA None 0 N/A
Ethionamide ethA, inhA, ndh, mshA None 0 N/A
Bold values indicate signiﬁcance at most frequent resistance mutation relative to drug.
–Locus number very small to yield meaningful comparisons.
a Italicized mutation = Low conﬁdence mutations.
b Excludes phylogenetically informative mutation gyrA.T80A.
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resistant RIF phenotype had rpoB mutations (sensitivity 88.6 %). One
previously treated patient of 54 patients with a susceptible RIF
phenotype had the rpoB.L511P mutation (speciﬁcity 98.1)1 (Tables 2A
and 4), as well as katG.S315T, rrs.A514C and embB.M306V resistance-
conferring mutations and was with the isolate having a RIF MIC of
320 μg/ml. Of the four isolates having phenotypic resistance without
detectable RIF resistance-conferring mutations and no evidence
of mixed coverage/infection, three had MIC around the cut-off
(MIC = 40 μg/ml) and one had MIC indicating low level RIF resistance
(MIC = 80 μg/ml), Table 5.
Of the 85 patients with an INH-resistant phenotype, 51 had katG
mutations (sensitivity 60.0%) whereas 14/85 had fabG1 mutations,
including one with ahpC mutation (sensitivity 16.5 %). A combination
of katG and fabG1 together with ahpC increased the sensitivity
for INH-related mutations to 71.8%. All isolates with INH resistance-
conferring mutations had INH-resistant phenotypes resulting in
genotype speciﬁcity of 100%, (Tables 2A and 4).
Of the 27 patients with a resistant phenotype to EMB, 17 had embAB
mutations (sensitivity 63.0 %). Eleven patients had a susceptible pheno-
type to EMB, but with embABmutations (speciﬁcity 82.5 %).
Of the 44 patients with a STR- resistant phenotype, ﬁve had
mutations in the rrs locus (sensitivity 11.4 %) and nine in the rpsLTable 3
Mycobacterium tuberculosis lineages stratiﬁed by resistance variants assigned by SNP
analysis.
Sub-lineage Overall n (%) RIF INH EMB STR
Beijing (lineage 2) 5 (5.3) 3 3 3 3
CAS-Delhi (lineage 3)a 18 (20.0) 7 13 10 4
Euro-American (Lineage 4)
LAM 11 (12.2) 4 10 3 2
S-type 7 (7.8) 1 4 0 0
T2-Uganda 36 (40.0) 16 19 7 7
ill-deﬁned (lineage 4)⁎ǂ 11 (12.2) 4 10 4 0
Unknown⁎ 2 (2.1) 1 2 1 0
Total 90 32 61 28 16
ǂ=X1=6, T2=1, T=2, andH1=2, Unknown=Uand T3-ETH, RIF= rifampicin, INH=
isoniazid, EMB= ethambutol, STR = streptomycin.
⁎ Lineage assigned by http://tbinsight.cs.rpi.edu/.
a One with no resistance SNP detected had mixed coverages of lineage 3 and lineage 4.locus (sensitivity 20.5 %). A combination of rrs and rpsL increased
the sensitivity for STR resistance-conferring mutations to 31.88%
(Tables 2A and 4).
4. Discussion
Molecular diagnostic methods are revolutionizing drug resistance
testing in tuberculosis, especially in the high-burden countries where
phenotypic methods are scarcely available. Ours is one of the ﬁrst stud-
ies to use WGS on a population-representative sample of RIF and/or
INH-resistant strains from sub-Saharan Africa, showing the potential
use of sequencing for complementing DRSs or surveillance in this
setting. Speciﬁcally, our results indicate which mutations may be
important to include in assays to replace phenotypic DST where this
reference standard for drug resistance surveillance cannot be feasibly
applied.
However, these ﬁndings also raise questions about the value of
phenotypic DST versus sequencing, since among survey patients who
were reported as resistant to RIF and INH, WGS for RIF, compared
to DST on LJ proportion (culture) method, had a sensitivity of only
88.6% and speciﬁcity of 98.1%. The low sensitivity of rpoB mutations
for detecting phenotypic resistance is unusual, yet the incomplete
speciﬁcity may indicate poor performance of the reference standard.
The only patient reported as susceptible by phenotypic DST had
rpoB.L511P (MIC 320), a mutation that has been previously found to
be missed by culture-based DST (Rigouts et al., 2013; Van Deun et al.,
2013). This study also documents a variety of mutations in rpoB,
which have been found to have differentMICs including reproducibility
challenges in liquid culture systems (Jamieson et al., 2014; Ocheretina
et al., 2014; Rigouts et al., 2013). Such discordances, with poor clinical
outcome documented for these mutations, challenge the recommenda-
tion that preferably phenotypic DST should be undertaken using liquid
culture, in countries where these ‘disputed’ mutations are likely to be
more frequent. One patient had D516Y + I572F, and the rpoB.I572F
mutation, which is outside the rpoB “hot-spot” region, and has been
found in 30% of RIF resistant patients in Swaziland and at lower frequen-
cy among clinical isolates in Australia (Sanchez-Padilla et al., 2015; Yuen
et al., 1999). The mutations outside the rpoB “hot spot” region are more
likely to be missed in an Xpert MTB/RIF-based drug resistance survey/
surveillance. Our ﬁndings further support a recommendation for
combined phenotypic and molecular RIF DST.
Table 4
Sensitivity and speciﬁcity of genotypic compared with phenotypic drug susceptibility testing.
Resistant Susceptible Accuracy values
Drug Locusab with mutation without mutation with mutation without mutation Sensitivity (%) Speciﬁcity (%)
RIF rpoB 31 4⁎ 1 53 88.6 98.1
INH katG 51 34 0 5 60.0 100.0
fabG1+ ahpC 14 71 0 5 16.5 100.0
katG and/or fabG1+ ahpC 61 24 0 5 71.8 100.0
EMB embAB 17 10 11 52 63.0 82.5
STR rrs 5 39 0 46 11.4 100.0
rpsL 9 35 2 44 20.5 95.7
rrs and/or rpsL 14 3 2 44 31.8 95.7
RIF = rifampicin, INH = isoniazid, EMB= ethambutol, STR = streptomycin.
⁎ Excludes one patient with no genotypic resistance but with mixed infection.
a Includes high and/or low conﬁdence according to TBdreamDB and patients with more than one resistance conferring mutations.
b Excludes phylogenetically informative mutations, shown in supplementary ﬁle 1.
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phenotypically resistant to RIF yet with wild-type genotype, despite
excellent results of QC and EQA in the surveys, mixed sequence
coverage as well as MICs around the break-point were the most likely
explanations of these discordances.
The twoMDR-TB patients with rpoB.S531L concurrent with compen-
satory rpoC N698S and V483Amutations suggest that these strains have
circulated longer and were able to select for compensatory mutations
that may enhance transmission (de Vos et al., 2013), although both
patients were previously treated for tuberculosis and these mutations
may have developed de novo in these patients. Of the three MDR-TB
patients involved in a cluster, all of Beijing lineage, one had rpoC
N698S.While theDRS design does not permit inferences on transmission
rates, the diversity of resistance mutations and low clustering suggest
that MDR-TB in Uganda is not caused by a limited number of resistant
clones that are actively transmitted. Follow-up surveillance of the one
small Beijing MDR cluster would however be warranted.
Mutations at the katG gene were the most frequent resistance
markers for INH, followed by fabG1. Mutations at katG codon 315 have
been associated with unfavourable treatment outcome and high-level
INH resistance (Ando et al., 2010; Huyen et al., 2013; Tolani et al.,
2012). Although there is limited data on the role of ahpC mutations
towards INH resistance, the only patient with an ahpC mutation also
had an INH resistance phenotype. At global level the proportion of
mutations in the katG is correlated with tuberculosis incidence, i.e.
transmission rates (Cohen et al., 2004). However, the low-level INH
resistance conferred by fabG1 alone, or even the higher level resistance
conferred by katG, may still be overcome by higher doses of INH
(Katiyar et al., 2008). Furthermore, the combination of katG and fabG1
promoter mutations tends to confer very high MICs (Vilcheze and
Jacobs, 2014) that obviate the further use of INH. Twenty-four (44.4%)
of the INH phenotypic resistant patients were found to have wild type
Mycobacterium tuberculosis in ahpC, inhA, fabG1, katG or ndh, although
we do not know the level of INH resistance, as the survey results were
only interpreted at 0.2 μg/mL conﬁrming the limited sensitivity of INHTable 5
Clinical, phenotypic and genotypic characteristics ofMycobacterium tuberculosis strains with ri
ID Age/sex HIV Previous TB
treatment
Phenotypic drug
resistance†
Lineage WGS
561 25, F Negative Yes RIF T2-Uganda WT
581 24, M Positive Yes INH, STR CAS-Delhi rpoB.L51
592 28, M Negative Yes RIF, STR T2-Uganda WT
602 20, M Negative Yes RIF, INH, EMB, STR T2-Uganda WT
607⁎ 42, M Negative Yes RIF, INH, STR CAS-Delhi katG.S31
618 35, M Negative Yes RIF, INH, STR T2-Uganda WT
RIF = rifampicin, INH = isoniazid, EMB = ethambutol, STR = streptomycin, MTB = Mycoba
sequencing, † =drug resistance testing (DST) performed using Lowenstein Jensen (LJ); RIF (40 m
interpreted at week four.
⁎ Mixed coverage of resistance and lineage.susceptibility testing using genotypic methods. Since the impact on
phenotypic resistance of each variant is different, a sequencing
approach could offer an optimally early and accurate diagnosis.
The high frequency of EMBdiscordance between genotypic andphe-
notypic testing reported in previous and the current study indicates the
challenges of EMB resistance testing using conventional methods. The
difference between the epidemiological cutoff (ECOFF) and MIC for
EMB is small (Cui et al., 2014). This complicates EMB phenotypic DST,
warranting larger studies to directly correlate different EMB mutations
with patient outcome so as to clarify their clinical importance.
Mutations at rpsL codon 43 have been previously associated with
MDR-TB (Jnawali et al., 2013; Spies et al., 2011) and found to carry no
ﬁtness cost (Spies et al., 2013). Indeed, we found 7/9 (77.8%) of patients
with rpsL codon 43 to have MDR-TB, however, two patients with
mutations at codon 43 had susceptible STR phenotype. Mutations at
the rrs locus have been associated with resistance to aminoglycosides
(Georghiou et al., 2012; Jugheli et al., 2009). We found 4/5 (80.0 %)
patients with mutations at the rrs locus to have MDR-TB, which
indicates pre-XDR TB.Mutations at rpsL and rrs occurred independently,
indicating a possible unique mechanism of their occurrence, which can
be exploited in new molecular diagnostic tools for STR resistance.
Overall, looking at the fourmain TB drugs, ourﬁndings are in agreement
with the previous studies (Dominguez et al., 2016).
Phenotypic DST for PZA was not performed in the current study.
Similar to previous studies (Cuevas-Cordoba et al., 2013; Napiorkowska
et al., 2014), among the eleven patients with pncA mutations, nine
(81.8%) different mutations were identiﬁed. In Uganda PZA is included
in both treatment regimens for susceptible and MDR-TB patients. The
fact that 32.3% of the MDR-TB patients also had pncAmutations raises
the question whether continued use of PZA in MDR-TB treatment
regimens for these patients still adds beneﬁt (Chang et al., 2012;
Miotto et al., 2015), a question which has to date not been sufﬁciently
addressed.
Only four (4.4%) MDR-TB patients were found to have resistance-
conferring mutations to injectables, of which three were mutationsfampicin discordance between phenotypic DST, MIC and rpoBmutation analysis.
rpoB-PCR MIC99
(μg/ml)
Final
interpretation
WT 40 S
1P, embB.M306V, katG.S315T, rrs.A514C Pro511(CCG) 320 R
WT 80 R
WT 40 S
5T WT N320 R
WT 40 S
cterium tuberculosis, MIC = minimum inhibition concentration, WGS = whole genome
g/mL), INH (0.2 mg/mL) and STR (10 mg/mL) interpreted at week six and EMB (2 mg/mL)
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presence of resistance conferring mutations to ﬂuoroquinolones, linez-
olid (rrl), para-aminosalisylic acid (thyA), ethionamide (ethA, inhA,
ndh,mshA), cross-resistance to STR, amikacin, capreomycin kanamycin
(gidB, tlyA) or kanamycin (eis) among these patients conﬁrms that
most MDR-TB in Uganda is not yet complicated by resistance to 2nd
line drugs.
Our study has limitations. First, our selection criteria only considered
patients with RIF and/or INH phenotypic resistance, precluding
prevalence estimates across the entire DRSs. While this selection did
allow us to look at gene mutations in a population-representative
sample of isolateswith phenotypic resistance to the twodrugs that deﬁne
MDR-TB, it could provide only limited information about resistance-
conferring mutations in isolates that were phenotypically susceptible.
As a consequence, speciﬁcity estimates for genotypic resistance for RIF
related to isolates that were phenotypically resistant to INH and vice
versa, which may have introduced bias.
Similarly, our results for EMB, STR and PZA may not be representa-
tive for all resistance to these drugs in Uganda. Secondly, we only man-
aged to obtain isolates from 66.2% of the eligible patients, and had less
power to correlate patient characteristic and drug resistance mutations.
Nevertheless, the strength of this study, one of the ﬁrst of its kind, con-
sists of the genome sequence based screen for all resistance conferring
mutations embedded in a nationwide drug resistance survey.
5. Conclusions
Among tuberculosis patients in Uganda, resistance beyond ﬁrst-line
drugs as well as compensatory mutations remain low, and MDR-TB
isolates did not arise from a dominant clone. The reported important
“high conﬁdence” mutations, if included in molecular assays, can re-
place phenotypic DST where this reference standard for drug resistance
surveillance cannot be feasibly applied. However, the imperfect correla-
tion of drug resistance-conferring mutations with phenotypic testing
raises concerns, resolution of which requires larger studies that include
analysis of clinical outcomes. The one clone of MDR-TB of Beijing family
isolates in the South Western Uganda that needs to be monitored.
Together, these results are encouraging from a public health perspec-
tive, as effective MDR treatment regimens, combined with solid patient
support, stand a good chance to prevent the emergence of XDR-TB in
this setting.
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